Author name: Yali Friedman

Biotech: The “safe” drug bet? “Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”

Biotech: The “safe” drug bet? “Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”

Biotech execs have a sense of humor about elusive profits When Ernst & Young’s annual report on the biotechnology industry

Is That a Pilot in Your Pocket? “Somewhere in Florida, 25,000 disembodied rat neurons are thinking about flying an F-22.

Foresight or folly? Generics firms’ foray into NCEs A number of generics firms have, over the last few years, veered

Foresight or folly? Generics firms’ foray into NCEs A number of generics firms have, over the last few years, veered

How many trillions for a drug miracle? “Here’s a quick thought experiment about the current system for developing and paying

State biotech sector no miracle drug for creation of jobs “Ruth Scott’s job is to be the No. 1 cheerleader

Merck: Successor pill safer than Vioxx Merck & Co., the US drug maker that recalled its Vioxx painkiller because of

Big pharma’s pain could be biotech’s gain “Current problems besetting ‘big pharma’ could have a silver lining for the smaller